Summary
A retrospective open study was conducted to determine the efficacy of penicillin and ceftriaxone in children with skin manifestations of Lyme borreliosis (solitary erythema migrans, multiple erythemata, borrelial lymphocytoma) and neuroborreliosis, respectively. One hundred sixty children were treated with penicillin and 41 with ceftriaxone for an average of 12 days. Serum antibodies to borreliae were determined before therapy and 2–3 and 4–6 weeks thereafter. At admission 44%/26%, 8%/42%, and 40%/35% of erythema migrans, borrelial lymphocytoma and neuroborreliosis patients, respectively, were IgM/IgG positive. Four to 6 weeks after treatment the percentage of seropositives was 20%/15%, 8%/61%, and 21%/44%, respectively. A 3 months follow-up was completed with 151 children. No child showed clinical evidence of illness, nor were there abnormalities in laboratory parameters.
Zusammenfassung
In einer offenen, retrospektiven Studie an Kindern wurde die Wirksamkeit von Penicillin bei der Behandlung von Hautmanifestationen der Lyme-Borreliose (Erythema migrans, n=160, Borrelien-Lymphozytom, n=26) und die Wirksamkeit von Ceftriaxon zur Behandlung der Neuroborreliose (n=41) untersucht. Die Therapiedauer betrug durchschnittlich 12 Tage. Serum-Antikörper wurden vor der antibiotischen Behandlung und 2–3 und 4–6 Wochen danach bestimmt. Zum Zeitpunkt der ersten Untersuchung waren 44%/26%, 8%/42% und 40%/35% der Erythema migrans-, Borrelien-Lymphozytom-bzw. Neuroborreliose-Patienten IgM/IgG positiv. Vier bis 6 Wochen nach Behandlung war der Anteil der Seropositiven 20%/15%, 8%/61% bzw. 21%/44%. Untersuchungen 3 Monate nach Behandlung konnten bei 151 Kindern (65%) durchgeführt werden. Keines der Kinder zeigte klinische Anzeichen einer Erkrankung oder einer chronischen Form der Lyme-Borreliose, ebenso gaben die Ergebnisse der Laboratoriumsuntersuchungen keinen Hinweis auf Anomalien.
Similar content being viewed by others
References
Preac Mursic, V., Wilske, B., Schierz, D., Holburger, M., Suss, E. In vitro andin vivo susceptibility ofBorrelia burgdorferi. Eur. J. Clin. Microbiol. 6 (1987) 424–426.
Johnson, R. C., Kodner, C., Russel, M. In vitro andin vivo susceptibility of the Lyme disease spirochete,Borrelia burgdorferi, to four antimicrobial agents. Antimicrob. Agents Chemother. 31 (1987) 164–167.
Christen, H. J., Hanefeld, F. Neurologic complications of erythema-migrans disease in childhood — clinical aspects. Zbl. Bakt. Hyg. A. 263 (1987) 337–342.
Clark, J. A., Carlson, R. D., Sasaki, C. T. Facial paralysis in Lyme disease. Laryngoscope 95 (1985) 1341–1345.
Millner, M. M., Schimek, M. G., Spork, K. D., Schnizer, M., Stanek, G. Lyme borreliosis in children. A controlled clinical study based on ELISA values. Eur. J. Pediatr. 148 (1989) 527–530.
del Rio, M., McCracken Jr., G. H., Nelson, J. D., Chrane, D., Shelton, S. Pharmacokinetics in cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis. Antimicrob. Agents Chemother. 22 (1982) 622–627.
Müllegger, R. R., Millner, M. M., Stanek, G., Spork, K. D. Penicillin G sodium and ceftriaxone in the treatment of neuroborreliosis in children. A prospective study. Infection 19 (1991) 273–278.
Sköldenberg, B., Stiernstedt, G., Karlsson, M. Treatment of Lyme borreliosis with emphasis on neurological disease. Ann. N. Y. Acad. Sci. 539 (1988) 317–323.
Pfister, H. W., Preac Mursic, V., Wilske, B., Einhäupl, K. M. Cefotaxime versus penicillin G for acute neurological manifestations in Lyme borreliosis. A prospective randomised study. Arch. Neurol. 46 (1989) 1190–1193.
Pfister, H. W., Preac Mursic, V., Wilske, B. Randomised comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J. Infect. Dis. 163 (1991) 311–318.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Krbkova, L., Stanek, G. Therapy of Lyme borreliosis in children. Infection 24, 170–173 (1996). https://doi.org/10.1007/BF01713333
Issue Date:
DOI: https://doi.org/10.1007/BF01713333